Loading...
Knockdown of PKM2 and GLS1 expression can significantly reverse oxaliplatin-resistance in colorectal cancer cells
Clinical treatment for colorectal cancer (CRC) thus far encounters a huge challenge due to oxaliplatin-resistance. As crucial rate-limiting enzymes in aerobic glycolysis and glutaminolysis, pyruvate kinase M2 type (PKM2) and kidney-type glutaminase (GLS1) are proposed to carry important implications...
Na minha lista:
| Udgivet i: | Oncotarget |
|---|---|
| Main Authors: | , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
Impact Journals LLC
2017
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5546471/ https://ncbi.nlm.nih.gov/pubmed/28498807 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.17396 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|